Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) in Q1 CY2025, with sales flat year on year at $6.67 billion. The ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims it used speaker ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV ...

Storm clouds hung low above a community center in Jackson, where pastor Andre Devine invited people inside for lunch. Hoagies ...

Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that ...

Even after decades of research, there is no cure for the disease HIV causes, AIDS. But lenacapavir, born out of research on ...

Metformin use in patients with HIV and type 2 diabetes who had at least 2 years of exposure to effective ART showed no significant effect on immune reconstitution.

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan ...